buildleaf glp 1 oral solution GLP-1 Research Center GLP-1 Research Center | California
Description
As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to incomeraising questions for both Medicaid and Medicare.
Is anyone else seeing this pattern in their practice
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits
Compounders were expected to cease production of tirzepatide by March 2025 and semaglutide by May 2025, yet both remain active in the market
